ANAPTYSBIO, INC (ANAB)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Collaboration revenue | 22,263 | 27,771 | 30,017 | 10,971 |
| Research and development | 37,824 | 41,180 | 42,212 | 41,997 |
| General and administrative | 10,609 | 14,130 | 10,562 | 9,295 |
| Total operating expenses | 48,433 | 55,310 | 52,774 | 51,292 |
| Loss from operations | -26,170 | -27,539 | -22,757 | -40,321 |
| Other income (expense), net | 3,531 | 1,902 | -5 | - |
| Interest income | 3,654 | 4,413 | 5,324 | 4,623 |
| Non-cash interest expense for the sale of future royalties | 19,606 | 18,061 | 15,413 | 10,953 |
| Total other expense, net | -12,421 | -11,746 | -10,094 | -6,330 |
| Loss before income taxes | -38,591 | -39,285 | -32,851 | -46,651 |
| Provision for income taxes | 39 | 44 | - | 9 |
| Net loss | -38,630 | -39,329 | -32,851 | -46,660 |
| Unrealized (loss) gain on available for sale securities | -167 | -144 | 1,174 | 209 |
| Comprehensive loss | -38,797 | -39,473 | -31,677 | -46,451 |
| Basic (in dollars per share) | -1.34 | -1.28 | -1.14 | -1.71 |
| Basic (in shares) | 28,810,000 | 30,644,000 | 28,893,000 | 27,356,000 |
| Diluted (in dollars per share) | -1.34 | -1.28 | -1.14 | -1.71 |
| Diluted (in shares) | 28,810,000 | 30,644,000 | 28,893,000 | 27,356,000 |